H56 Comparison of the efficacy and safety of candesartan cilexetil 4, 8 and 12 mg with placebo and enalapril 10 mg in patients with mild to moderate essential hypertension

Franke, H

doi:10.1016/s0895-7061(97)88977-7

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All members of this drug class combine an excellent tolerability with efficacy that is at least as great as that of ACE inhibitors and other first-line antihypertensive drugs (25)(26)(27)(28)(29). All members of this drug class combine an excellent tolerability with efficacy that is at least as great as that of ACE inhibitors and other first-line antihypertensive drugs (25)(26)(27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

“…The AT 1 -receptor blockers are now accepted as an important advance in hypertension therapy. All members of this drug class combine an excellent tolerability with efficacy that is at least as great as that of ACE inhibitors and other first-line antihypertensive drugs (25)(26)(27)(28)(29). However, it is important to establish if any one AT 1 -receptor blocker offers efficacy benefits over any other.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring

Nisse-Durgeat

Mouret

et al. 2006

International Journal of Clinical Practice

View full text Add to dashboard Cite

This double-blind, randomised, controlled study compared the efficacy of candesartan cilexetil 8 mg (n = 87) and losartan 50 mg (n = 89), once daily for 6 weeks, relative to placebo (n = 80) in patients with mild-to-moderate essential hypertension (diastolic blood pressure (DBP): 95-115 mmHg). Ambulatory BP measurements were done every 15 min over 36 h. At the end of the 6-week treatment, the mean change in DBP between the baseline and the 0-24-h period after the last dose of study medication was greater in patients receiving candesartan cilexetil 8 mg (-7.3 mmHg +/- 6.9 mmHg) compared with losartan 50 mg (-5.1 mmHg +/- 4.9 mmHg) (p < 0.05) or placebo (0.3 mmHg +/- 6.5 mmHg) (p < 0.001). The mean change in systolic BP (SBP) during this time was greater in patients receiving candesartan cilexetil 8 mg (-10.8 mmHg +/- 11.3 mmHg), or losartan 50 mg (-8.8 mmHg +/- 8.9 mmHg) than placebo (1.2 mmHg +/- 9.9 mmHg) (p < 0.001). Candesartan cilexetil 8 mg was associated with a greater reduction in DBP and SBP, relative to placebo, when compared with losartan 50 mg, during both daytime and night-time, and between 12 and 24 h after dosing (p < 0.001). Both active treatments were well tolerated. In patients with mild-to-moderate essential hypertension, candesartan cilexetil 8 mg therefore had greater, more consistent antihypertensive efficacy throughout the day and the night, and long-lasting efficacy after the last dose, compared with losartan 50 mg. This greater efficacy is maintained with an excellent tolerability associated with members of the angiotensin Il type 1-receptor blocker class.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring

Nisse-Durgeat

Mouret

et al. 2006

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

Comparative pharmacology of the angiotensin II receptor antagonists

Dzielak

1998

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

The non-peptide angiotensin II (AII) receptor antagonists are a new class of compounds that are continuing to be developed as therapeutic agents for the treatment of hypertension, heart failure (HF) and chronic renal disease (CRD). Several of these compounds are currently available for therapeutic use in the USA and the European community with several more in clinical trials and in development. Compounds in this new class are as effective as angiotensin converting enzyme (ACE) inhibitors in treating hypertensive patients and appeared to have a similar therapeutic profile to ACE inhibitors in patients with HF and CRD. One clinical advantage of the AII receptor antagonists over ACE inhibitors is an improved side-effect profile with the absence of the persistent dry cough associated with ACE inhibitor therapy. To date, it is clear that the AII receptor antagonists are effective antihypertensive agents. Clinical trials are currently in progress to determine the therapeutic efficacy of these drugs in the treatment of HF and progressive renal disease.

show abstract

Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension

Guthrie

Saini

Herman

et al. 1998

Clinical Drug Investigation

View full text Add to dashboard Cite

H56 Comparison of the efficacy and safety of candesartan cilexetil 4, 8 and 12 mg with placebo and enalapril 10 mg in patients with mild to moderate essential hypertension

Cited by 4 publications

References 0 publications

A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring

A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring

Comparative pharmacology of the angiotensin II receptor antagonists

Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension

Contact Info

Product

Resources

About